Latest Breaking News On - ஜெஃப்ரி விடுவிக்கப்பட்டவர் - Page 2 : comparemela.com

CET AB Science SA (Euronext - FR0010557264 - AB) today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy met its predefined primary endpoint. Patents related to study AB12003 results are being filed and detailed results of study AB12003 will be presented during a webcast with Key Opinion Leaders that will be held as soon as patents have been filed. About AB12003 Study AB12003 was an international, multicenter, randomized, double blind, placebo-controlled, 2-parallel group, Phase 3 study in metastatic castrate resistant prostate cancer (mCRPC) eligible to chemotherapy. The study aimed to compare the efficacy and safety of masitinib (6.0 mg/kg/day) in combination with docetaxel versus placebo in combination with docetaxel. Docetaxel was combined with prednisone.

United statesFrance generalArthur rouillJeffrey freedmanKey opinion leadersNorth americaEuronext parisDes marchஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்ஜெஃப்ரி விடுவிக்கப்பட்டவர்விசை கருத்து தலைவர்கள்வடக்கு அமெரிக்காதேஸ் அணிவகுப்பு